New Family of Peptide Antibiotics Discovered That Kill Vancomycin-Resistant Bacteria
A novel discovery pipeline applied to 227 bacterial strains identified paenitracins — a new family of bacitracin-type peptide antibiotics with potent activity against drug-resistant pathogens including vancomycin-resistant Enterococcus.
Quick Facts
What This Study Found
The researchers identified a novel family of nonribosomal peptides designated paenitracins, representing the first bacitracin-type peptides reported in the Paenibacillus genus. Key features include:
- Three previously unseen amino acid substitutions distinguish paenitracins from canonical bacitracins
- Potent activity against gram-positive pathogens, including vancomycin-resistant Enterococcus faecium E155
- Discovered through a novel MassQL (mass spectrometry query language)-based approach combined with molecular networking
The study also provided a comprehensive genus-wide inventory of nonribosomal peptides produced by 227 taxonomically diverse Paenibacillus strains, establishing a resource for future antibiotic discovery.
Key Numbers
How They Did This
Researchers collected 227 taxonomically diverse plant-associated Paenibacillus strains and analyzed their nonribosomal peptide (NRP) production. They developed a targeted discovery pipeline using MassQL (mass spectrometry query language) combined with feature-based molecular networking to identify NRPs containing basic amino acids. Genomics-guided analysis complemented the metabolomics data. Antimicrobial activity was tested against gram-positive pathogens including drug-resistant strains. The full NRP chemical space of Paenibacillus was mapped at the genus level.
Why This Research Matters
Antimicrobial resistance is one of the most urgent global health threats, with drug-resistant infections killing over 1.2 million people annually. Vancomycin-resistant Enterococcus is classified by the WHO as a high-priority pathogen for new antibiotic development. The discovery of paenitracins — natural peptide antibiotics effective against VRE — directly addresses this need. The discovery pipeline itself may be even more valuable than the specific compounds, as it provides a systematic way to find new peptide antibiotics from nature.
The Bigger Picture
Natural products remain the richest source of antibiotic candidates, and nonribosomal peptides are among the most important classes of natural antibiotics (polymyxins, vancomycin, and bacitracin are all peptide-based). This study demonstrates that combining modern metabolomics and genomics tools can uncover novel peptide antibiotics from bacterial collections — essentially using AI and mass spectrometry to mine nature's antibiotic factory more efficiently. As antibiotic resistance worsens, this type of accelerated natural product discovery becomes increasingly critical.
What This Study Doesn't Tell Us
Antimicrobial activity was demonstrated against specific lab strains; broader spectrum testing including additional resistant isolates would strengthen the case. The study focused on gram-positive activity — effectiveness against gram-negative bacteria was not reported. Drug-like properties (stability, toxicity, pharmacokinetics) of paenitracins have not been characterized. The discovery pipeline is resource-intensive and may not be accessible to all research groups. Moving from discovery to clinical development requires significant additional investment.
Questions This Raises
- ?Can paenitracins be developed into clinically useful antibiotics with acceptable safety and pharmacokinetic profiles?
- ?Do paenitracins have a mechanism of action distinct from canonical bacitracin that reduces cross-resistance?
- ?Could this MassQL-based discovery pipeline identify novel peptide antibiotics from other bacterial genera?
Trust & Context
- Key Stat:
- Active against vancomycin-resistant Enterococcus Paenitracins are a new peptide antibiotic family discovered by screening 227 bacterial strains, effective against one of the most concerning drug-resistant pathogens
- Evidence Grade:
- This is a preclinical natural product discovery study with in vitro antimicrobial activity data. The identification and structural characterization of a novel peptide family is solid, but the compounds are at the earliest stage of development with no animal testing or clinical data.
- Study Age:
- Published in 2026, this is a very recent study applying cutting-edge metabolomics and genomics approaches to antibiotic discovery, directly relevant to the ongoing antimicrobial resistance crisis.
- Original Title:
- Paenitracins, a novel family of bacitracin-type nonribosomal peptide antibiotics produced by plant-associated Paenibacillus species.
- Published In:
- mSystems, e0149625 (2026)
- Authors:
- Machushynets, Nataliia V, Elsayed, Somayah S, Du, Chao, Lysenko, Vladyslav, de la Cruz, Mercedes, Sanchez, Pilar, Genilloud, Olga, Martin, Nathaniel I, Liles, Mark R, van Wezel, Gilles P
- Database ID:
- RPEP-15628
Evidence Hierarchy
Frequently Asked Questions
What are nonribosomal peptides and why are they important for antibiotics?
Nonribosomal peptides (NRPs) are compounds made by bacteria and fungi using specialized enzyme machinery, rather than the ribosome that makes most proteins. This allows them to incorporate unusual amino acids and structures that give them powerful biological activities. Many of our most important antibiotics — including vancomycin, polymyxin, and bacitracin — are NRPs. Their structural diversity makes them a rich source of new antibiotic candidates.
Why is vancomycin-resistant Enterococcus such a serious threat?
Vancomycin-resistant Enterococcus (VRE) is a major hospital-acquired infection that is extremely difficult to treat because vancomycin is often considered the 'last resort' antibiotic for gram-positive infections. VRE causes bloodstream infections, urinary tract infections, and wound infections, particularly in immunocompromised patients. Finding new antibiotics that can kill VRE is a WHO priority, making the discovery of paenitracins particularly significant.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15628APA
Machushynets, Nataliia V; Elsayed, Somayah S; Du, Chao; Lysenko, Vladyslav; de la Cruz, Mercedes; Sanchez, Pilar; Genilloud, Olga; Martin, Nathaniel I; Liles, Mark R; van Wezel, Gilles P. (2026). Paenitracins, a novel family of bacitracin-type nonribosomal peptide antibiotics produced by plant-associated Paenibacillus species.. mSystems, e0149625. https://doi.org/10.1128/msystems.01496-25
MLA
Machushynets, Nataliia V, et al. "Paenitracins, a novel family of bacitracin-type nonribosomal peptide antibiotics produced by plant-associated Paenibacillus species.." mSystems, 2026. https://doi.org/10.1128/msystems.01496-25
RethinkPeptides
RethinkPeptides Research Database. "Paenitracins, a novel family of bacitracin-type nonribosomal..." RPEP-15628. Retrieved from https://rethinkpeptides.com/research/machushynets-2026-paenitracins-a-novel-family
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.